Bio-Rad Laboratories Inc (BIO)

Return on equity (ROE)

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Net income (ttm)	US$ in thousands	-637,300	-159,300	-428,400	-191,214	-3,627,564	-6,027,464	-1,935,064	-93,150	4,254,200	6,665,600	4,050,800	4,100,400	3,806,300	3,520,600	1,947,000	1,579,400	1,758,700	376,700	904,800	574,000
Total stockholders’ equity	US$ in thousands	8,741,130	8,416,200	8,446,890	9,763,720	9,615,250	8,477,470	8,945,040	10,203,300	13,685,200	15,332,400	11,594,900	10,609,100	9,889,690	8,825,140	7,353,400	6,293,080	5,756,840	5,131,190	5,486,810	4,863,860
ROE		-7.29%	-1.89%	-5.07%	-1.96%	-37.73%	-71.10%	-21.63%	-0.91%	31.09%	43.47%	34.94%	38.65%	38.49%	39.89%	26.48%	25.10%	30.55%	7.34%	16.49%	11.80%

December 31, 2023 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $-637,300K ÷ $8,741,130K
= -7.29%

Bio-Rad Laboratories Inc.'s return on equity (ROE) has shown significant fluctuations over the past eight quarters. In Q4 2023, the ROE was reported at -7.29%, indicating that the company's net income generated a negative return compared to shareholders' equity. This was an improvement from the previous quarter, where the ROE was -1.82%.

However, the ROE has been mostly negative in recent quarters, with Q2 2022 and Q3 2022 showing particularly low ROE figures of -71.39% and -21.77% respectively. The sharp decline in ROE in Q2 2022 compared to Q1 2022 (-0.99%) and the subsequent improvement in Q3 2022 indicate significant volatility in the company's profitability.

It is important for stakeholders to closely monitor Bio-Rad Laboratories Inc.'s ROE performance to assess the efficiency of the company in generating returns for shareholders. The negative ROE figures suggest that the company may be facing challenges in maximizing shareholder wealth, and management may need to implement strategies to improve profitability and operational efficiency.